Allen Capital Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.51M Buy
2,172
+70
+3% +$82.6K 0.2% 100
2026
Q2
$2.52M Buy
2,102
+184
+10% +$188K 0.21% 98
2026
Q1
$1.76M Buy
1,918
+16
+0.8% +$16.2K 0.16% 103
2025
Q4
$2.04M Buy
1,902
+461
+32% +$441K 0.19% 97
2025
Q3
$1.1M Sell
1,441
-383
-21% -$285K 0.1% 123
2025
Q2
$1.42M Buy
1,824
+254
+16% +$197K 0.15% 101
2025
Q1
$1.3M Buy
1,570
+170
+12% +$141K 0.15% 101
2024
Q4
$1.08M Buy
1,400
+536
+62% +$444K 0.13% 107
2024
Q3
$765K Buy
864
+176
+26% +$158K 0.09% 120
2024
Q2
$623K Buy
688
+117
+20% +$93.6K 0.09% 122
2024
Q1
$444K Buy
571
+134
+31% +$95.4K 0.06% 137
2023
Q4
$255K Buy
+437
New +$255K 0.04% 155
2022
Q1
– Sell
-810
Closed -$224K – 178
2021
Q4
$224K Buy
+810
New +$205K 0.03% 156

Other funds holding LLY

Allen Capital Group's LLY Position: Q3 2026 in Review

Allen Capital Group increased its Eli Lilly (LLY) stake by 3.3% in Q3 2026, buying an estimated $82.6K and bringing the position to 2,172 shares worth $2.51M. The position accounts for 0.2% of the portfolio, ranked #100.

Allen Capital Group first reported a position in LLY in Q4 2021 and has held it in 13 quarters since. The position peaked at $2.52M in Q2 2026. 2,091 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Allen Capital Group held 2,172 shares of Eli Lilly worth $2.51M as of Q3 2026.
  • Allen Capital Group bought 70 Eli Lilly shares in Q3 2026, an estimated $82.6K.
  • Eli Lilly made up 0.2% of Allen Capital Group's portfolio in Q3 2026, its #100 holding.
  • Allen Capital Group first reported a position in Eli Lilly in Q4 2021 and has held it in 13 quarters since.
  • Allen Capital Group's Eli Lilly position peaked at $2.52M in Q2 2026.
  • 2,091 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Allen Capital Group's 13F filing for Q3 2026, filed 27 Oct 2026.